VERTEX PHARMACEUTICALS INC / MA
VRTXUS売上高
$12.0B
百万USD
営業利益
$4.2B
百万USD
純利益
$4.0B
百万USD
ROE
21.2%
最新FY
EPS
$15.32
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $1.7B | $653M | $2.49 |
| FY2021 | Q2 | $1.8B | $67M | $0.26 |
| FY2021 | Q3 | $2.0B | $852M | $3.28 |
| FY2021 | FY | $7.6B | $2.3B | $9.01 |
| FY2022 | Q1 | $2.1B | $762M | $2.96 |
| FY2022 | Q2 | $2.2B | $811M | $3.13 |
| FY2022 | Q3 | $2.3B | $931M | $3.59 |
| FY2022 | FY | $8.9B | $3.3B | $12.82 |
| FY2023 | Q1 | $2.4B | $700M | $2.69 |
| FY2023 | Q2 | $2.5B | $916M | $3.52 |
| FY2023 | Q3 | $2.5B | $1.0B | $3.97 |
| FY2023 | FY | $9.9B | $3.6B | $13.89 |
| FY2024 | Q1 | $2.7B | $1.1B | $4.21 |
| FY2024 | Q2 | $2.6B | $-3.6B | $-13.92 |
| FY2024 | Q3 | $2.8B | $1.0B | $4.01 |
| FY2024 | FY | $11.0B | $-536M | $-2.08 |
| FY2025 | Q1 | $2.8B | $646M | $2.49 |
| FY2025 | Q2 | $3.0B | $1.0B | $3.99 |
| FY2025 | Q3 | $3.1B | $1.1B | $4.20 |
| FY2025 | FY | $12.0B | $4.0B | $15.32 |
| FY2026 | Q1 | $3.0B | $1.0B | $4.02 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $3.0B | $4.2B | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| 営業利益 | $10M | $123M | $635M | $1.2B | $2.9B | $2.8B | $4.3B | $3.8B | $-233M | $4.2B |
| 純利益 | $-112M | $263M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | $-536M | $4.0B |
| 総資産 | $2.9B | $3.5B | $6.2B | $8.3B | $11.8B | $13.4B | $18.2B | $22.7B | $22.5B | $25.6B |
| 純資産 | $1.3B | $2.0B | $4.4B | $6.1B | $8.7B | $10.1B | - | - | - | - |
| 自己資本 | $1.2B | $2.0B | $4.4B | - | - | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| 営業CF | $236M | $845M | $1.3B | $1.6B | $3.3B | $2.6B | $4.1B | $3.5B | $-493M | $3.6B |
| EPS | $-0.46 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| BPS | $4.66 | $7.99 | $17.35 | - | - | $39.67 | $54.12 | $68.06 | $63.90 | $73.48 |
| ROE | -9.7% | 13.0% | 47.3% | - | - | 23.2% | 23.9% | 20.6% | -3.3% | 21.2% |